Clinical Trial

Novel Approaches to Target MECOM/EVI1 in AML

Recruiting
View on ClinicalTrials.gov →
Summary
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-21.
Status change: Not Yet Recruiting → Recruiting 2023-12-22
Trial Details
NCT Number NCT05839392
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions AML, Adult
Enrollment 24 participants
Start Date 2023-12-13
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-12-29